In terms of other antihypertensive medications, two recent systematic reviews and meta-analyses found that angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers do not appear to increase the risk of developing severe COVID-19 stages of the disease or mortality [55, 56]. This evidence concerns the gene ACE and COVID-19.